JP2019528271A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528271A5 JP2019528271A5 JP2019508842A JP2019508842A JP2019528271A5 JP 2019528271 A5 JP2019528271 A5 JP 2019528271A5 JP 2019508842 A JP2019508842 A JP 2019508842A JP 2019508842 A JP2019508842 A JP 2019508842A JP 2019528271 A5 JP2019528271 A5 JP 2019528271A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- gene
- deletion
- smallpox
- chikungunya
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903295 | 2016-08-19 | ||
| AU2016903295A AU2016903295A0 (en) | 2016-08-19 | Viral Vaccines | |
| PCT/AU2017/050879 WO2018032057A1 (en) | 2016-08-19 | 2017-08-18 | Viral vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528271A JP2019528271A (ja) | 2019-10-10 |
| JP2019528271A5 true JP2019528271A5 (https=) | 2020-05-14 |
Family
ID=61195904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508842A Pending JP2019528271A (ja) | 2016-08-19 | 2017-08-18 | ウイルスワクチン |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10905759B2 (https=) |
| EP (2) | EP4331676A3 (https=) |
| JP (1) | JP2019528271A (https=) |
| KR (1) | KR20190050787A (https=) |
| CN (1) | CN109862909A (https=) |
| AR (1) | AR110624A1 (https=) |
| AU (1) | AU2017313450B2 (https=) |
| CA (2) | CA3034282A1 (https=) |
| CL (1) | CL2019000405A1 (https=) |
| IL (1) | IL264893B (https=) |
| MA (1) | MA45994A (https=) |
| MX (1) | MX2019001919A (https=) |
| MY (1) | MY200887A (https=) |
| NZ (1) | NZ750578A (https=) |
| SG (1) | SG11201900814QA (https=) |
| TW (1) | TWI728173B (https=) |
| WO (1) | WO2018032057A1 (https=) |
| ZA (1) | ZA201900641B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004403A (es) * | 2018-10-22 | 2021-10-22 | Icellkealex Therapeutics Llc | Virus vaccinia mutantes y uso de los mismos. |
| TW202203966A (zh) * | 2020-03-31 | 2022-02-01 | 澳大利亞商賽門蒂斯公司 | 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗 |
| CN112362877B (zh) * | 2020-10-27 | 2024-04-12 | 江苏先声医学诊断有限公司 | 一种mbp重组蛋白以及其应用 |
| KR102864666B1 (ko) * | 2025-04-21 | 2025-09-29 | 대한민국 | 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU694519B2 (en) * | 1994-04-29 | 1998-07-23 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
| CN1418951A (zh) * | 2001-05-23 | 2003-05-21 | 广州绿健生物技术有限公司 | 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法 |
| CN102703393A (zh) * | 2002-05-16 | 2012-10-03 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| EP2269619A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
| KR20040015624A (ko) | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물 |
| DE602004015418D1 (de) * | 2003-02-18 | 2008-09-11 | Helmholtz Zentrum Muenchen | Rekombinantes mva und verfahren zur erzeugung davon |
| EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
| EP1683870A1 (en) * | 2005-01-24 | 2006-07-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vaccines based on the use of MVA |
| GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| WO2012040474A2 (en) | 2010-09-23 | 2012-03-29 | Baxter International Inc. | Recombinant viral vectors and methods for inducing an immune response to yellow fever virus |
| NZ630642A (en) | 2013-03-15 | 2016-01-29 | Sementis Ltd | Immune modulation |
| DK3063278T3 (en) * | 2013-11-01 | 2018-06-06 | Sementis Ltd | PREPARATION OF VIRAL VECTORS |
| WO2016086980A1 (en) * | 2014-12-02 | 2016-06-09 | Consejo Superior De Investigaciones Cientificas | Vaccine composition |
| BR112018015696A2 (pt) | 2016-02-03 | 2018-12-26 | Geovax Inc | composições e métodos para gerar uma resposta imune para um flavivírus |
-
2017
- 2017-08-18 WO PCT/AU2017/050879 patent/WO2018032057A1/en not_active Ceased
- 2017-08-18 SG SG11201900814QA patent/SG11201900814QA/en unknown
- 2017-08-18 KR KR1020197007662A patent/KR20190050787A/ko not_active Ceased
- 2017-08-18 EP EP23215911.1A patent/EP4331676A3/en active Pending
- 2017-08-18 CA CA3034282A patent/CA3034282A1/en active Pending
- 2017-08-18 MX MX2019001919A patent/MX2019001919A/es unknown
- 2017-08-18 EP EP17840633.6A patent/EP3500280A4/en not_active Withdrawn
- 2017-08-18 NZ NZ750578A patent/NZ750578A/en unknown
- 2017-08-18 AU AU2017313450A patent/AU2017313450B2/en active Active
- 2017-08-18 JP JP2019508842A patent/JP2019528271A/ja active Pending
- 2017-08-18 CA CA3265584A patent/CA3265584A1/en active Pending
- 2017-08-18 TW TW106128111A patent/TWI728173B/zh not_active IP Right Cessation
- 2017-08-18 MA MA045994A patent/MA45994A/fr unknown
- 2017-08-18 US US16/325,539 patent/US10905759B2/en active Active
- 2017-08-18 IL IL264893A patent/IL264893B/en unknown
- 2017-08-18 CN CN201780063830.0A patent/CN109862909A/zh active Pending
- 2017-08-18 MY MYPI2019000845A patent/MY200887A/en unknown
- 2017-08-18 AR ARP170102311A patent/AR110624A1/es unknown
-
2019
- 2019-01-30 ZA ZA2019/00641A patent/ZA201900641B/en unknown
- 2019-02-14 CL CL2019000405A patent/CL2019000405A1/es unknown
-
2020
- 2020-12-22 US US17/130,165 patent/US20210113684A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6818797B2 (ja) | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 | |
| JP2019528271A5 (https=) | ||
| CA2422094C (en) | Vaccination method | |
| Herbert et al. | Recombinant adenovirus expressing the haemagglutinin of peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR | |
| JP2016510989A5 (https=) | ||
| Webster et al. | Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers | |
| BR112018076633A2 (pt) | mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| CA2408328A1 (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
| Mendes et al. | Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1 | |
| JP2011041578A5 (https=) | ||
| Weyer et al. | Poxvirus-vectored vaccines for rabies—a review | |
| EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF | |
| JP2016074727A5 (https=) | ||
| JP2024105526A5 (https=) | ||
| RU2015115785A (ru) | Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака | |
| JP2010523138A5 (https=) | ||
| JP2025084850A5 (https=) | ||
| Denzler et al. | Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques | |
| Kyriakis | Tomorrow’s vector vaccines for small ruminants | |
| Akkutay-Yoldar et al. | Diagnosis and phylogenetic analysis of orf virus in Aleppo and Saanen goats from an outbreak in Turkey | |
| Bennett et al. | Recombinant vaccinia viruses protect against Clostridium perfringens α-toxin | |
| Medkour et al. | Canine leishmaniosis and first report of Leishmania infantum in the blood of equids in Kabylia (Algeria) | |
| EA200701801A1 (ru) | Применение модифицированных поксвирусов для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов | |
| Meseda et al. | Percutaneous vaccination as an effective method of delivery of MVA and MVA-vectored vaccines |